PET Imaging Characteristics of C11-Acetate in Patients With Recurrent Prostate Carcinoma

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

Positron emission tomography (PET) imaging evaluation in men with recurrent prostate cancer to select patients who may benefit from directed therapy

Key facts

Study ID

NCT01304485

Run by

Phoenix Molecular Imaging

People needed

2000

Starts

2011-04-01

Expected to finish

2019-01-01

Last updated by the study team

2019-03-07

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• recurrent prostate cancer (detectable PSA following radical prostatectomy or rising PSA in patients with radiation therapy as the primary treatment)

You may not qualify if…

• < 18 years old
• claustrophobic patients

Where it is running

• Phoenix Molecular Imaging — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.